Literature DB >> 33423839

How should we conduct pandemic vaccination?

Jane Williams1, Chris Degeling2, Jodie McVernon3, Angus Dawson4.   

Abstract

Vaccination plays an important role in pandemic planning and response. The possibility of developing an effective vaccine for a novel pandemic virus is not assured. However, as we have seen with SARS-CoV-2 vaccine development, with sufficient resources and global focus, successful outcomes can be achieved in a relatively short period. However even when vaccine is available it will initially be scarce. When one becomes available, how should it be distributed? In this paper we explicate how ethical thinking that is carefully attuned to context is essential to decisions about how we should conduct vaccination in a pandemic where demand exceeds supply. We focus on two key issues. First, setting the aims for a pandemic vaccination programme. Second, thinking about the means of delivering a chosen aim. We outline how pandemic vaccine distribution strategies can be implemented with distinct aims, e.g. protecting groups at greater risk of harm, saving the most lives, or ensuring societal benefit. Each aim will result in a focus on a different priority population and each strategy will have a different benefit-harm profile. Once we have decided our aim, we still have choices to make about delivery. We may achieve at least some ends via direct or indirect strategies. Such policy decisions are not merely technical, but necessarily involve ethics. One important general issue is that such planning decisions about distribution will always be made under conditions of uncertainty about vaccine safety and effectiveness. However, planning how to distribute vaccine for SARS-CoV-2 is even harder because we understand relatively little about the virus, transmission, and its immunological impact in the short and long term.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Ethics; Pandemic infection; Pandemic vaccination strategies; Pandemic vaccine; SARS-CoV-2; Values

Year:  2021        PMID: 33423839     DOI: 10.1016/j.vaccine.2020.12.059

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

Review 1.  Prioritization of COVID-19 vaccination. The added value of the "VALIDATE" approach.

Authors:  Pietro Refolo; Bart Bloemen; Barbara Corsano; John Grin; Iñaki Gutierrez-Ibarluzea; Bjørn Hofmann; Wija Oortwijn; Laura Sampietro-Colom; Lars Sandman; Gert Jan van der Wilt; Dario Sacchini
Journal:  Health Policy       Date:  2022-05-20       Impact factor: 3.255

2.  Variability in Forest Visit Numbers in Different Regions and Population Segments before and during the COVID-19 Pandemic.

Authors:  Magdaléna Pichlerová; Dilek Önkal; Anthony Bartlett; Jozef Výbošťok; Viliam Pichler
Journal:  Int J Environ Res Public Health       Date:  2021-03-26       Impact factor: 3.390

Review 3.  Rifampicin for COVID-19.

Authors:  George D Panayiotakopoulos; Dimitrios T Papadimitriou
Journal:  World J Virol       Date:  2022-03-25

Review 4.  COVID-19 vaccines for children and adolescents in Africa: aligning our priorities to situational realities.

Authors:  Kaymarlin Govender; Patrick Nyamaruze; Neil McKerrow; Anna Meyer-Weitz; Richard G Cowden
Journal:  BMJ Glob Health       Date:  2022-02

5.  Disease burden and vaccination priorities in Colombia.

Authors:  Lina María Quitián; Carlos E Rodríguez-Martinez; Mónica P Sossa-Briceño; Jorge Alberto Cortés
Journal:  Vaccine       Date:  2022-02-15       Impact factor: 4.169

6.  Application of Traditional Vaccine Development Strategies to SARS-CoV-2.

Authors:  Halie M Rando; Ronan Lordan; Alexandra J Lee; Amruta Naik; Nils Wellhausen; Elizabeth Sell; Likhitha Kolla; Covid-Review Consortium; Anthony Gitter; Casey S Greene
Journal:  ArXiv       Date:  2022-08-16

7.  A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures.

Authors:  Cécile Tran Kiem; Clément R Massonnaud; Daniel Levy-Bruhl; Chiara Poletto; Vittoria Colizza; Paolo Bosetti; Arnaud Fontanet; Amélie Gabet; Valérie Olié; Laura Zanetti; Pierre-Yves Boëlle; Pascal Crépey; Simon Cauchemez
Journal:  EClinicalMedicine       Date:  2021-07-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.